14.08

0.43% 0.06

After Hours: 14.08

Enanta Pharmaceuticals Inc (ENTA)

Overview News Price History Option Chain Financials Discussions Forecast

Enanta Pharmaceuticals Inc stock is traded at $14.08, with a volume of 233.45K. It is up +0.43% in the last 24 hours and up +5.71% over the past month. Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Previous Close:

$14.02

Open:

$13.92

24h Volume:

233.45K

Relative Volume:

1.08

Market Cap:

$410.09M

Revenue:

$69.21M

Net Income/Loss:

$-61.98M

P/E Ratio:

-5.4264

EPS:

-2.5947

Net Cash Flow:

$-9.61M

1W Performance:

+3.53%

1M Performance:

+5.71%

6M Performance:

-8.63%

1Y Performance:

+58.38%

1-Day Range:

$13.45

$14.22

1-Week Range:

$13.12

$14.29

52-Week Range:

$7.05

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name

Enanta Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

617 607 0800

Address

4 KINGSBURY AVENUE, WATERTOWN, MA

Employee

120

Twitter

@EnantaPharma

Next Earnings Date

2026-08-10

Latest SEC Filings

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTA Enanta Pharmaceuticals Inc	14.08	382.42M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Nov-14-25	Initiated	JP Morgan	Overweight
Oct-01-25	Upgrade	Jefferies	Hold → Buy
Jul-28-25	Resumed	H.C. Wainwright	Buy
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight
Aug-08-23	Downgrade	Jefferies	Buy → Hold
Dec-09-22	Initiated	H.C. Wainwright	Buy
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line
Oct-07-21	Initiated	Jefferies	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Nov-24-20	Initiated	Evercore ISI	Underperform
Aug-28-20	Resumed	ROTH Capital	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight
May-24-19	Initiated	Wolfe Research	Outperform
Apr-23-19	Upgrade	Berenberg	Hold → Buy
Dec-13-18	Initiated	Berenberg	Hold
Jun-06-18	Initiated	ROTH Capital	Buy
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-21-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-11-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Apr-28-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	Barclays	Underweight
Oct-23-15	Downgrade	Barclays	Equal Weight → Underweight
Oct-23-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform

View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

Sep 06, 2026

(ENTA) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Sep 06, 2026

Sep 05, 2026

ENTA stock holds steady as Enanta Pharmaceuticals focuses on antiviral pipeline - AD HOC NEWS

Sep 05, 2026

Sep 04, 2026

Enanta Pharmaceuticals stock gains after new SEC filing and solid cash position - AD HOC NEWS

Sep 04, 2026

Sep 01, 2026

Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire

Sep 01, 2026

Enanta stock holds in the low teens as investors look to recent trial and earnings progress - AD HOC NEWS

Sep 01, 2026

Aug 23, 2026

Enanta (ENTA) Watch: Finishes 2.59% Up at $13.47 for the Current Session; Boundary Watch: the Price Remains Bounded by the Supplied Support and ResistanceMoney Flow Index - vinanet.vn

Aug 23, 2026

Aug 20, 2026

Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S - GuruFocus

Aug 20, 2026

Aug 14, 2026

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - Kalkine

Aug 14, 2026

Aug 12, 2026

Enanta Pharmaceuticals Announces Q3 Fiscal 2026 Financial Results - Kalkine Media

Aug 12, 2026

Aug 11, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 11, 2026

Aug 10, 2026

Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade

Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts

Aug 10, 2026

Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus

Aug 10, 2026

Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada

Aug 10, 2026

Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com

Aug 10, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com

Aug 10, 2026

Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - tradingview.com

Aug 10, 2026

Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo

Aug 10, 2026

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - Barchart.com

Aug 10, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire

Aug 10, 2026

ENANTA PHARMACEUTICALS ($ENTA) Releases Q3 2026 Earnings - Quiver Quantitative

Aug 10, 2026

Aug 07, 2026

Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Market Profile - dars.gov.et

Aug 07, 2026

Aug 06, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 06, 2026

(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026

Aug 03, 2026

Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat

Aug 03, 2026

Jul 30, 2026